Coverage
-
September 15, 2022
The Second Circuit on Thursday affirmed a lower court's decision rebuffing biotechnology company Amyris' arbitration bid in cannabinoid maker Lavvan's $881 million patent and trade secrets suit over cannabis development, ruling that a research agreement between the companies doesn't clearly warrant the arbitration.
3 other articles on this case.
View all »